Aug 2026
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer
Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.
Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al.
· bioRxiv · 0 citations